Usefulness of combining admission brain natriuretic peptide (BNP) plus hospital discharge bioelectrical impedance vector analysis (BIVA) in predicting 90 days cardiovascular mortality in patients with acute heart failure
Authors:
- On Behalf Of Great NetworkONOn Behalf Of Great Network
- Luigi Maria CastelloLCLuigi Maria Castello
- 16 December 2016
- journal article
- research article
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 12 (4) , 445-451
Abstract
Heart failure is a disease characterized by high prevalence and mortality, and frequent rehospitalizations. The aim of this study is to investigate the prognostic power of combining brain natriuretic peptide (BNP) and congestion status detected by bioelectrical impedance vector analysis (BIVA) in acute heart failure patients. This is an observational, prospective, and a multicentre study. BNP assessment was measured upon hospital arrival, while BIVA analysis was obtained at the time of discharge. Cardiovascular deaths were evaluated at 90 days by a follow up phone call. 292 patients were enrolled. Compared to survivors, BNP was higher in the non-survivors group (mean value 838 vs 515 pg/ml, p < 0.001). At discharge, BIVA shows a statistically significant difference in hydration status between survivors and non-survivors [respectively, hydration index (HI) 85 vs 74, p < 0.001; reactance (Xc) 26.7 vs 37, p < 0.001; resistance (R) 445 vs 503, p < 0.01)]. Discharge BIVA shows a prognostic value in predicting cardiovascular death [HI: area under the curve (AUC) 0.715, 95% confidence interval (95% CI) 0.65–0.76; p < 0.004; Xc: AUC 0.712, 95% CI 0.655–0.76, p < 0.007; R: AUC 0.65, 95% CI 0.29–0.706, p < 0.0247]. The combination of BIVA with BNP gives a greater prognostic power for cardiovascular mortality [combined receiving operating characteristic (ROC): AUC 0.74; 95% CI 0.68–0.79; p < 0.001]. In acute heart failure patients, higher BNP levels upon hospital admission, and congestion detected by BIVA at discharge have a significant predictive value for 90 days cardiovascular mortality. The combined use of admission BNP and BIVA discharge seems to be a useful tool for increasing prognostic power in these patients.Keywords
This publication has 25 references indexed in Scilit:
- Markers of Decongestion, Dyspnea Relief, and Clinical Outcomes Among Patients Hospitalized With Acute Heart FailureCirculation: Heart Failure, 2013
- The emerging role of biomarkers and bio-impedance in evaluating hydration status in patients with acute heart failureClinical Chemistry and Laboratory Medicine (CCLM), 2012
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESCEuropean Heart Journal, 2012
- Fluid Overload Assessment and Management in Heart Failure PatientsSeminars in Nephrology, 2012
- Optimizing fluid management in patients with acute decompensated heart failure (ADHF): the emerging role of combined measurement of body hydration status and brain natriuretic peptide (BNP) levelsHeart Failure Reviews, 2011
- Use of BNP and Bioimpedance to Drive Therapy in Heart Failure PatientsCongestive Heart Failure, 2010
- Analytic and Clinical Utility of a Next-Generation, Highly Sensitive Cardiac Troponin I Assay for Early Detection of Myocardial InjuryClinical Chemistry, 2009
- Prognostic Utility of B-Type Natriuretic Peptide Assessment in Stable Low-Risk Outpatients With Nonischemic Cardiomyopathy After Decompensated Heart FailureJACC, 2008
- Congestion in Acute Heart Failure Syndromes: An Essential Target of Evaluation and TreatmentThe American Journal of Medicine, 2006
- A new method for monitoring body fluid variation by bioimpedance analysis: The RXc graphKidney International, 1994